NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Global North America CRISPR Technology Market Size, Share and Trends Analysis

North America CRISPR Technology market size was $3.1B in 2023, forecasted to hit $10.2B by 2032, growing at 14.2% CAGR.

Revenue, 2023

$3.1B

Forecast, 2032

$10.2B

CAGR, 2024-2032

14.2%

Report Coverage

North America

Code: north-america-crispr-technology-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The North America CRISPR technology market was valued at approximately $3.1 billion in 2023 and is projected to reach $10.2 billion by 2032, expanding at a CAGR of 14.2%. Growth is driven by rising genetic disorder prevalence, pharmaceutical R&D investment, and expanding clinical trials. CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics lead the competitive landscape. North America commands over 42% of the global market share, supported by robust regulatory frameworks and venture capital funding.

02

Key Highlights

1

Market projected to grow from $3.1B to $10.2B by 2032 at 14.2% CAGR

2

North America holds 42% global share led by US with 38% worldwide

3

CRISPR kits and reagents segment dominates at 35% market share

03

Market Overview

Market Context

The CRISPR technology market is in a high-growth phase driven by therapeutic breakthroughs, expanding clinical trials, and increasing biotech investment. North America leads globally with advanced infrastructure and regulatory clarity. Casgevy's approval set a commercial precedent.

The CRISPR technology market is experiencing high growth fueled by therapeutic breakthroughs, expanding gene editing applications, and increasing biotech investments. North America dominates globally with advanced research infrastructure. Casgevy's FDA approval in 2023 marked a pivotal commercial milestone for the industry.

Market Stage

High growth

Adoption Level

Growing

Key Trends

CRISPR therapeutics gaining FDA approvals accelerating clinical adoptionBase editing and prime editing expanding application scopePharma-biotech collaborations driving pipeline growthAI-integrated bioinformatics enhancing gene editing precision
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 14.2%

Base Year (2023)

$3.1B

Forecast (2032)

$10.2B

CAGR (2024-2032)

14.2%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$3.10B
2024$3.54B
2025$4.04B
2026$4.62B
2027$5.27B
2028$6.02B
2029$6.88B
2030$7.85B
2031$8.97B
2032$10.24B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

Sustained double-digit growth expected through 2032, propelled by expanding oncology pipelines, rare disease therapies, and agricultural applications. Delivery system innovations will unlock new therapeutic areas.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America42.0%15.1%United States
Europe30.0%12.8%Germany
Asia Pacific28.0%16.5%China

North America

#1
Share: 42.0%CAGR: 15.1%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 12.8%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising prevalence of genetic disorders worldwide
  • Increasing pharmaceutical R&D spending on gene therapies
  • Advancements in CRISPR delivery systems
06

Market Segmentation

By Application
Market share distribution across 5 segments
By Application — market share by segment, in percent.
SegmentShare
Drug Discovery & DevelopmentTarget identification, validation, and preclinical model development.40.0%
Genetic Disease TreatmentTherapeutic applications for monogenic and complex genetic disorders.25.0%
Agriculture & FoodCrop improvement, disease resistance, and livestock gene editing.15.0%
Industrial BiotechnologyMicrobial engineering for biofuels, enzymes, and chemical production.12.0%
DiagnosticsCRISPR-based molecular diagnostics including SHERLOCK and DETECTR platforms.8.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Product Type
Market share distribution across 5 segments
By Product Type — market share by segment, in percent.
SegmentShare
CRISPR Kits & ReagentsIncludes Cas9 enzymes, gRNA kits, and reagents for research applications.35.0%
CRISPR Therapeutics PipelineIn vivo and ex vivo therapeutic candidates across clinical trial stages.28.0%
Delivery SystemsViral and non-viral delivery platforms for targeted gene editing.18.0%
Software & BioinformaticsComputational tools for gRNA design, off-target prediction, and data analysis.12.0%
ServicesContract gene editing, screening, and custom CRISPR service offerings.7.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Pharmaceutical & Biotech Companies
  • Academic & Research Institutes
  • Contract Research Organizations
  • Hospitals & Clinics
07

Regional Analysis

1

North America

Lead: United States
CAGR: 15.1%Share: 42.0%

Dominant region driven by advanced research infrastructure, FDA approvals, and strong venture capital funding.

2

Europe

Lead: Germany
CAGR: 12.8%Share: 30.0%

Growing adoption supported by EU research grants and emerging therapeutic approvals.

3

Asia Pacific

Lead: China
CAGR: 16.5%Share: 28.0%

Fastest-growing region due to government investment and expanding biotech sector.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
38.0%
+14.8%
Germany
12.0%
+12.1%
China
15.0%
+17.3%
08

Competitive Landscape

C

CRISPR Therapeutics AG

Switzerland

Leader500M

Pioneered first FDA-approved CRISPR therapy Casgevy; strong oncology and hemoglobinopathy pipeline.

Global leader in CRISPR-based therapeutics, co-developer of Casgevy, the first FDA-approved CRISPR therapy for sickle cell disease.

E

Editas Medicine, Inc.

United States

Challenger200M

Leading in vivo and ex vivo gene editing with ophthalmology and oncology programs advancing in trials.

Clinical-stage genome editing company advancing in vivo and ex vivo CRISPR therapies with lead ophthalmology program EDIT101.

T

Thermo Fisher Scientific Inc.

United States

Follower200B

Dominant CRISPR reagents and tools supplier; launched FDA-grade Cas enzymes for clinical-grade applications.

Global leader in CRISPR reagents, kits, and enzymes serving research and clinical-grade gene editing applications.

09

Recent Developments

25
2025CRISPR Therapeutics

Expanded oncology pipeline with CTX112 IND filing targeting solid tumors

24
2024Editas Medicine

BRILLIANCE Phase 1/2 trial showed 79% vision improvement in EDIT-101 treated patients

10

Regulatory Landscape

FDA guidance on human gene therapy products incorporating genome editingEMA Committee for Advanced Therapies (CAT) framework for CRISPR-based medicines
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys

Secondary research

  • Industry reports
  • Company financials

Validation: Triangulation method

12

Strategic Takeaways

Investors

High-growth opportunity with 14.2% CAGR; therapeutics segment offers highest upside

Operators

Invest in delivery systems and bioinformatics to capture emerging market segments

Strategists

North America remains primary market but Asia Pacific offers fastest growth potential

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.